Advicenne Secures Its Cash Runway to Q2 2027 through a Bond Financing of a Nominal Amount of up to €3.8 Million

Advicenne Secures Its Cash Runway to Q2 2027 through a Bond Financing of a Nominal Amount of up to €3.8 Million

Regulatory News:

Advicenne S.A. (“Advicenne” or the “Company”) (Euronext Growth Paris - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, announced today that it has secured a two-tranche financing of a nominal amount of up to €3.8 million, through the issuance of bonds subscribed by Cemag Invest and Didier Laurens, Chairman of the Board and CEO of Advicenne, and new investors, Europe Offering and a fund managed by L1 Capital.

This financing extends Advicenne’s financial outlook to the second quarter of 2027, within the framework of the ongoing safeguard proceedings. It provides the Company with the flexibility required to finalize the U.S. registration of ADV7103, its proprietary asset, in distal Renal Tubular Acidosis (dRTA) and to execute its financial restructuring through the ongoing safeguard proceedings.

Didier Laurens, Chairman and CEO of Advicenne, stated: “I would like to sincerely thank the investors, and especially Cemag Invest, for their valuable support and renewed confidence. This financing is perfectly tailored to meet the Company’s cash requirements. Its structure will enable us to complete our safeguard plan with all stakeholders in an efficient manner, while preserving our flexibility to continue Advicenne’s strategic development, particularly obtaining marketing authorization for ADV7103 in the United States. I have personally committed to participating in this financing, as a mark of my confidence in the success of both our development projects and financial restructuring.”